Identification of a novel SIRT7 inhibitor as anticancer drug candidate

Ji Hye Kim, Dahee Kim, Suk Joon Cho, Kwan Young Jung, Jong Hoon Kim, Jun Mi Lee, Hee Jung Jung, Kwang Rok Kim

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)


Sirtuins (SIRT1-7), a class of deacetylases, play major roles in DNA damage repair, aging, and metabolism in yeast and in mammals. SIRT7 is localized in the nucleolus. It regulates cellular processes, including genomic stability, rDNA transcription, and cell proliferation, and plays a role in tumorigenesis. SIRT7 deacetylates its substrates histone H3 (at lysine 18) and p53. p53, a tumor suppressor, induces apoptosis or cell cycle arrest and is stabilized by acetylation. p53 deacetylation at K382 by SIRT7 suppressed cancer cell growth by attenuating p53 activity. Therefore, identification of novel SIRT7 enzyme inhibitors is important. In this study, we found a novel inhibitor of SIRT7 (ID: 97491) that decreased SIRT7 activity in a dose-dependent manner. ID: 97491 induced expression of p53 and its acetylation by inhibited SIRT7. Moreover, ID: 97491 upregulated apoptotic effects through the caspase related proteins and inhibited cancer growth in vivo. The study results suggest that ID: 97491 can be a potential candidate to inhibit the deacetylase activity of SIRT7 and prevent tumor progression by increasing p53 stability through acetylation at K373/382.

Original languageEnglish
Pages (from-to)451-457
Number of pages7
JournalBiochemical and biophysical research communications
Issue number2
Publication statusPublished - 2019 Jan 8


  • Apoptosis
  • Deacetylation
  • Inhibitor
  • SIRT7
  • p53

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Identification of a novel SIRT7 inhibitor as anticancer drug candidate'. Together they form a unique fingerprint.

Cite this